Multi-Center Phase 2 Trial of Single-Agent Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma
Phase of Trial: Phase II
Latest Information Update: 26 Apr 2018
At a glance
- Drugs Amrubicin (Primary)
- Indications Bladder cancer; Urogenital cancer
- Focus Therapeutic Use
- 23 Dec 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 07 Apr 2015 Planned End Date changed from 1 Feb 2015 to 1 Dec 2015, according to to ClinicalTrials.gov record.
- 07 Apr 2015 Status changed from recruiting to active, no longer recruiting, according to to ClinicalTrials.gov record.